Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP

Prostate Cancer and Prostatic Diseases volume 8, pages 274–279 (2005)Cite this article

Abstract

Most tumor cells are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis but sparing to normal cells, thus providing therapeutic potential for clinical use. Some tumor cells are resistant to TRAIL-induced cell death while the sensitivity could be recruited with the existence of some chemical agents. In this study, human prostatic cancer cell line LNCaP was found to be resistant to TRAIL-induced apoptosis while it could be restored to TRAIL sensitivity with combination treatment of low concentration of doxorubicin. TRAIL receptor-1 (DR4) and TRAIL receptor-2 (DR5) were upregulated under the treatment of doxorubicin and verified to be responsible for TRAIL-mediated signal transduction. Furthermore, caspase-8 and caspase-3 were activated and drove their autocleavage into programmed cell death. Interestingly, apoptosis-inhibitory protein c-FLIP, but not Bcl-2 and XIAP was downregulated after doxorubicin treatment. Taken together, these findings suggested that the pathway of cell apoptosis induced by TRAIL was intact but under negative control. Subtoxic concentration of doxorubicin effectively boosted TRAIL sensitivity via depletion of antiapoptotic protein. These findings support the new strategies for killing tumors with TRAIL and chemical agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Ashkenazi A, Dixit V . Death receptors: signaling and modulation. Science 1998; 281: 1305–1308.

    CAS  PubMed  Google Scholar 

  2. Zhang XD et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747–2753.

    CAS  PubMed  Google Scholar 

  3. Bodmer J et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241–243.

    Article  CAS  PubMed  Google Scholar 

  4. Walczak H et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.

    Article  CAS  PubMed  Google Scholar 

  5. Salvesen G, Dixit VM . Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 1999; 96: 10964–10967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Green D . Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695–698.

    Article  CAS  PubMed  Google Scholar 

  7. Pan GH et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.

    Article  CAS  PubMed  Google Scholar 

  8. Pan GH, Ni J, Wei YF, Dixitet VM . TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998; 424: 41–45.

    Article  CAS  PubMed  Google Scholar 

  9. Srinivasula S et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/INFR1-induced apoptosis. J Biol Chem 1997; 272: 18542–18545.

    Article  CAS  PubMed  Google Scholar 

  10. Adams JM, Cory S . Life-or-death decisions by the BCL-2 protein family. Trends Biochem Sci 2001; 26: 61–66.

    Article  CAS  PubMed  Google Scholar 

  11. Tamm I et al. IAP-family protein surviving inhibits caspasse activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315–5320.

    CAS  PubMed  Google Scholar 

  12. Tang D, Lahti JM, Grenet J, Kidd VJ . Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J Biol Chem 1999; 274: 7245–7252.

    Article  CAS  PubMed  Google Scholar 

  13. Jian K et al. Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines. Br J Haematol 2003; 123: 921–932.

    Article  Google Scholar 

  14. Jinghai W et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900–3906.

    Google Scholar 

  15. Leverkus M et al. Regulation of tumor necrosis factor-related apoptosis inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553–559.

    CAS  PubMed  Google Scholar 

  16. Irmler M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195.

    Article  CAS  PubMed  Google Scholar 

  17. Mitsiades N et al. Intracellular regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162–2171.

    Article  CAS  PubMed  Google Scholar 

  18. David WC et al. c-FLIP is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704–3714.

    Article  Google Scholar 

  19. MacFarlane M et al. Mechanisms of resistant to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukemia. Oncogene 2002; 21: 6809–6818.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang XD et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164: 3961–3970.

    Article  CAS  PubMed  Google Scholar 

  21. Tepper CG, Seldin MF . Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein–Barr virus tumorigenesis in Burkitt's lymphoma. Blood 1999; 94: 1727–1737.

    CAS  PubMed  Google Scholar 

  22. Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ . Failure of BCL-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett 2000; 471: 93–98.

    Article  CAS  PubMed  Google Scholar 

  23. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC . The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914–6925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ng CP, Zisman A, Bonavida B . Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002; 53: 286–299.

    Article  CAS  PubMed  Google Scholar 

  25. Deveraux QL, Takahashi R, Salvvesen GS, Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 338: 300–304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Xinhua hospital, Shanghai Second Medical University, Shanghai, PR China

    J Kang & F Chen

  2. Department of Intensive Care Unit, Shanghai Children Medical Center, Shanghai, PR China

    J Bu

  3. Division of Immunology, Paediatric Research Institute, Shanghai Second Medical University, Shanghai, PR China

    Y Hao

Authors
  1. J Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Kang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, J., Bu, J., Hao, Y. et al. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 8, 274–279 (2005). https://doi.org/10.1038/sj.pcan.4500798

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500798

Keywords

This article is cited by

Search

Advanced search

Quick links